These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29285660)

  • 1. Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.
    Kumru B; Kaplan DS; Oztürk Hismi B; Celik H
    Cell Mol Neurobiol; 2018 Jul; 38(5):1033-1038. PubMed ID: 29285660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients.
    Sitta A; Barschak AG; Deon M; Barden AT; Biancini GB; Vargas PR; de Souza CF; Netto C; Wajner M; Vargas CR
    Int J Dev Neurosci; 2009 May; 27(3):243-7. PubMed ID: 19429389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studying the effect of large neutral amino acid supplements on oxidative stress in phenylketonuric patients.
    Kumru B; Ozturk Hismi B; Kaplan DS; Celik H
    J Pediatr Endocrinol Metab; 2019 Mar; 32(3):269-274. PubMed ID: 30835252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-carnitine blood levels and oxidative stress in treated phenylketonuric patients.
    Sitta A; Barschak AG; Deon M; de Mari JF; Barden AT; Vanzin CS; Biancini GB; Schwartz IV; Wajner M; Vargas CR
    Cell Mol Neurobiol; 2009 Mar; 29(2):211-8. PubMed ID: 18814025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients.
    Sitta A; Vanzin CS; Biancini GB; Manfredini V; de Oliveira AB; Wayhs CA; Ribas GO; Giugliani L; Schwartz IV; Bohrer D; Garcia SC; Wajner M; Vargas CR
    Cell Mol Neurobiol; 2011 Apr; 31(3):429-36. PubMed ID: 21191647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress in phenylketonuric patients.
    Vargas CR; Wajner M; Sitta A
    Mol Genet Metab; 2011; 104 Suppl():S97-9. PubMed ID: 21813309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients.
    Sitta A; Manfredini V; Biasi L; Treméa R; Schwartz IV; Wajner M; Vargas CR
    Mutat Res; 2009; 679(1-2):13-6. PubMed ID: 19665577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress in patients with phenylketonuria.
    Sirtori LR; Dutra-Filho CS; Fitarelli D; Sitta A; Haeser A; Barschak AG; Wajner M; Coelho DM; Llesuy S; Belló-Klein A; Giugliani R; Deon M; Vargas CR
    Biochim Biophys Acta; 2005 Apr; 1740(1):68-73. PubMed ID: 15878743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-carnitine protects DNA oxidative damage induced by phenylalanine and its keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria.
    Faverzani JL; Steinmetz A; Deon M; Marchetti DP; Guerreiro G; Sitta A; de Moura Coelho D; Lopes FF; Nascimento LVM; Steffens L; Henn JG; Ferro MB; Brito VB; Wajner M; Moura DJ; Vargas CR
    Metab Brain Dis; 2021 Oct; 36(7):1957-1968. PubMed ID: 34216350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of antioxidant enzymes, total sialic acid, lipid bound sialic acid, vitamins and selected amino acids in children with phenylketonuria.
    Ekin S; Dogan M; Gok F; Karakus Y
    Pediatr Res; 2018 Dec; 84(6):821-828. PubMed ID: 30135593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal serum phenylalanine for adult patients with phenylketonuria.
    Okano Y; Nagasaka H
    Mol Genet Metab; 2013 Dec; 110(4):424-30. PubMed ID: 24094552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress in phenylketonuria: what is the evidence?
    Ribas GS; Sitta A; Wajner M; Vargas CR
    Cell Mol Neurobiol; 2011 Jul; 31(5):653-62. PubMed ID: 21516352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of oxidative stress parameters in treated phenylketonuric patients.
    Sitta A; Barschak AG; Deon M; Terroso T; Pires R; Giugliani R; Dutra-Filho CS; Wajner M; Vargas CR
    Metab Brain Dis; 2006 Dec; 21(4):287-96. PubMed ID: 17146735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria.
    Sanayama Y; Nagasaka H; Takayanagi M; Ohura T; Sakamoto O; Ito T; Ishige-Wada M; Usui H; Yoshino M; Ohtake A; Yorifuji T; Tsukahara H; Hirayama S; Miida T; Fukui M; Okano Y
    Mol Genet Metab; 2011 Jul; 103(3):220-5. PubMed ID: 21514861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of antioxidant status in phenylketonuric patients.
    Artuch R; Colomé C; Sierra C; Brandi N; Lambruschini N; Campistol J; Ugarte D; Vilaseca MA
    Clin Biochem; 2004 Mar; 37(3):198-203. PubMed ID: 14972641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary biomarkers of oxidative stress and plasmatic inflammatory profile in phenylketonuric treated patients.
    Deon M; Sitta A; Faverzani JL; Guerreiro GB; Donida B; Marchetti DP; Mescka CP; Ribas GS; Coitinho AS; Wajner M; Vargas CR
    Int J Dev Neurosci; 2015 Dec; 47(Pt B):259-65. PubMed ID: 26456498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant status in hyperphenylalaninemia.
    Sierra C; Vilaseca MA; Moyano D; Brandi N; Campistol J; Lambruschini N; Cambra FJ; Deulofeu R; Mira A
    Clin Chim Acta; 1998 Aug; 276(1):1-9. PubMed ID: 9760015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress in phenylketonuria: future directions.
    Rocha JC; Martins MJ
    J Inherit Metab Dis; 2012 May; 35(3):381-98. PubMed ID: 22116469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased peripheral of brain-derived neurotrophic factor levels in phenylketonuric patients treated with l-carnitine.
    Faverzani JL; Guerreiro G; Hammerschmidt TG; Lopes FF; Coelho DM; Sitta A; Mescka CP; Deon M; Wajner M; Vargas CR
    Arch Biochem Biophys; 2023 Nov; 749():109792. PubMed ID: 37863349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors that increase risk for poor adherence to phenylketonuria treatment in Brazilian patients.
    Teruya KI; Remor E; Schwartz IVD
    Am J Med Genet A; 2021 Jul; 185(7):1991-2002. PubMed ID: 33765361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.